Denali Therapeutics vs Passage BIO
DNLI and PASG side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How DNLI and PASG compare
Denali Therapeutics is the larger company, worth 234 times as much as Passage BIO ($3.0B against $12.9M).
Denali Therapeutics scores higher on the StockData Score (6 against 5 for Passage BIO), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | DNLI | PASG |
|---|---|---|
| Size and price | ||
| Market cap | $3.0B | $12.9M |
| Share price | $18.89 | $4.01 |
| Change, 1 year | 7.5% | −47.9% |
| Change, 5 years | −59.9% | −97.6% |
| Beta (5Y) | 1.66 | 1.63 |
| Employees | 503 | 24 |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.6× (better) | 258× |
| FCF yield | −14.5% | – |
| Profitability | ||
| Return on equity | −54.9% (better) | −212% |
| Return on invested capital | −343% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 8.37 (better) | 1.00 |
| Altman Z-score | 1.96 (better) | −54.03 |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 97.7% | 133% |
| Held by insiders | 6.6% | 27.6% |
| Insider net buying, 12 months | −$1.3M | $93.0K (better) |
| Short interest, % of float | 9.8% | 2.1% |
Go deeper
- DNLI stock overview
- DNLI income statement
- DNLI valuation and score
- PASG stock overview
- PASG income statement
- PASG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.